Systemic chemotherapeutic treatment of patients with breast cancer brain metastases
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16249Keywords:
blood-brain barrier, brain metastases, breast cancer, effectiveness of systemic anticancer therapy, prognostic factorsAbstract
Summary. Brain metastases of solid tumors are the most common intracranial neoplasms in adults. We provide a short overview of the role of the blood-brain barrier in the pathogenesis of breast cancer brain metastases, and the effectiveness of systemic anticancer therapy in the treatment of such patients.
References
Liubota R, Vereshchako R, Anikusko M, Liubota I. Management of brain metastases from solid tumors. In: Hamza A, Salem N, Eds. Cancer Management and Therapy. IntechOpen, 2018. DOI: 10.5772/intechopen.75447. Available from: https://www.intechopen.com/books/cancer-management-and-therapy/management-of-brain-metastases-from-solid-tumors
Griguolo G, Jacot W, Kantelhardt E, et al. External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases: a multicentric European experience. Breast 2017; 37: 36–41.
Subbiah IM, Lei X, Weinberg JS, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol 2015; 33: 2239–45.
Liubota R., Cheshuk V., Vereshchako R. et al. The impact of locoregional treatment on survival of patients with primary metastatic breast cancer. Exp Oncol 2017; 39: 75–7.
Wilhelm I, Fazakas C, Molnar K, et al. Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases. J Cereb Blood Flow Metab 2018; 38: 563–87.
Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013; 7: 27–34.
Gomez-Zepeda D, Taghi M, Scherrmann JM, et al. ABC Transporters at the blood-brain interfaces, their study models, and drug delivery implications in gliomas. Pharmaceutics 2019; 12: 20.
Lin X., DeAngelis L. M. Treatment of brain metastases. J Clin Oncol 2015; 33: 3475–84.
Fong CW. Permeability of the blood-brain barrier: molecular mechanism of transport of drugs and physiologically important compounds. J Membr Biol 2015; 248: 651–69.
Teleanu DM, Negut I, Grumezescu V, et al. Nanomaterials for drug delivery to the central nervous system. Nanomaterials (Basel) 2019; 9: E371.
Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: Current state of the art. Int J Nanomed 2017; 12: 5879–92.
Lombardi G, Di Stefano AL, Farina P, et al. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev 2014; 40: 951–9.
Seoane J, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Mol Oncol 2014; 8: 1120–31.
Addeo R, Sperlongano P, Montella L, et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 2012; 70: 603–9.
Cortés J, Rugo HS, Awada A, et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat 2017; 165: 329–41.
Siena, S, Crino L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010; 21: 655–61.
Naskhletashvili DR, Gorbunova VA, Bychkov MB, et al. Gemcitabine plus cisplatin in patients with heavily pretreated breast cancer with brain metastases. J Clin Oncol 2010; 28: Suppl abstr 1125.
Erten C, Demir L, Somali I, et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev 2013; 14: 3711–7.
Jacot W, Gerlotto-Borne MC, Thezenas S, et al. Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer 2010; 10: 1–10.
Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis. Eur J Cancer 2017; 84: 141–8.
Yap YS, Cornelio GH, Devi BC. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 2012; 107: 1075–82.
Freedman RA, Gelman RS, Melisko ME, et al. TBCRC 022: phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). J Clin Oncol 2017; 35: Suppl abstr 1005.
Fabi A, Alesini D, Valle E, et al. T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer. Breast 2018; 41: 137–43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
